Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.

AIDS (London, England) - 2 Jan 2013

Larrouy Lucile, Vivot Alexandre, Charpentier Charlotte, Bénard Antoine, Visseaux Benoit, Damond Florence, Matheron Sophie, Chene Geneviève, Brun-Vezinet Françoise, Descamps Diane

Abstract excerpt

OBJECTIVE: This study investigated the impact on virological outcome of the gag cleavage sites and the protease-coding region mutations in protease inhibitor-naive and protease inhibitor-experienced patients infected with HIV-2 receiving lopinavir (LPV) containing regimen. METHODS: Baseline gag and protease-coding region were sequenced in 46 HIV-2 group A-infected patients receiving lopinavir. Virological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to gag Gene Products, Human Immunodeficiency Virus
Share to HIV-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to pol Gene Products, Human Immunodeficiency Virus

Share to Protease Inhibitors

Share to Viral Load

Source

Identifiers

PMID: 23018441
DOI: 10.1097/QAD.0b013e32835a10d8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.PMID 23018441Read ↗

Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.Semantic proximity Read ↗

Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.Semantic proximity Read ↗

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.Semantic proximity Read ↗

Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.Semantic proximity Read ↗

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced PatientsSemantic proximity Read ↗

Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.Semantic proximity Read ↗

Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays.Semantic proximity Read ↗

Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.Semantic proximity Read ↗

Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.Semantic proximity Read ↗

HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience.Semantic proximity Read ↗

Mutations in HIV-1 gag cleavage sites and their association with protease mutations.Semantic proximity Read ↗

Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.